Newsroom

SEATTLE--(BUSINESS WIRE)--The Access to Advanced Health Institute (AAHI), a nonprofit biotech organization dedicated to developing vaccines and technologies for global health, today congratulates Eli Lilly and Company and Curevo Vaccine on Lilly’s acquisition of Curevo. Curevo’s lead asset, amezosvatein (CRV-101), is a Phase 3-ready subunit vaccine for the prevention of shingles (herpes zoster) that incorporates AAHI’s proprietary SLA-SE adjuvant. The acquisition underscores the growing recogni...

MINNEAPOLIS--(BUSINESS WIRE)--In celebration of Graco’s 100th anniversary, the Graco Foundation announced a $1 million Centennial Impact Initiative to support 10 Minnesota nonprofit organizations advancing self-sufficiency, stability and workforce development, including technical training and career pathways aligned with Minnesota’s manufacturing and industrial workforce needs. Through the initiative, each nonprofit partner will receive a $100,000 grant to commemorate Graco’s centennial anniver...

CARY, N.C.--(BUSINESS WIRE)--Cornerstone Building Brands unifies its metal solutions retail network under its industry-leading Mueller brand to strengthen customer experience....

SINGAPORE--(BUSINESS WIRE)--AM Best will sponsor and exhibit at the Insurance Council of New Zealand (ICNZ) Conference on 4 June 2026 in Aotea Centre, Auckland. Rob Curtis, managing director and chief executive officer of AM Best’s Singapore operations, and Peter Tsiakos, market development associate, AM Best, will be available at stand No. 10 to discuss the resources AM Best offers to insurance professionals, including Best’s Credit Ratings, Best’s Performance Assessment for Delegated Underwri...

OAKVILLE, Ontario--(BUSINESS WIRE)--Groupe de portefeuilles Harvest Inc. (« Harvest ») annonce la distribution en espèces finale de mai 2026 pour la distribution suivante pour le FNB Harvest de bons du Trésor du Canada pour le mois se terminant le 31 mai 2026. La distribution sera versée vers le 5 juin 2026 aux porteurs de parts inscrits le 29 mai 2026. Les détails concernant le montant final de la distribution en espèces par part sont les suivants : FNB Harvest Symbole TSX Distribution estimée...

OAKVILLE, Ontario--(BUSINESS WIRE)--Harvest Portfolios Group Inc. (“Harvest”) announces the final May 2026 cash distribution for the following distribution for the Harvest Canadian T-Bill ETF for the month ending May 31, 2026. The distribution will be paid on or about June 5, 2026 to unitholders of record on May 29, 2026. Details regarding the final per unit cash distribution amount is as follows: Harvest ETF TSX Ticker Cash Distribution Harvest Canadian T-Bill ETF TBIL  $0.0905 per unit For ad...

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz reminds investors of the upcoming May 29, 2026 deadline to participate as a lead plaintiff in the securities fraud class action lawsuit filed on behalf of investors who acquired Pinterest, Inc. (“Pinterest” or the “Company”) (NYSE: PINS) securities between February 7, 2025 and February 12, 2026, inclusive (the “Class Period”). IF YOU ARE AN INVESTOR WHO LOST MONEY ON PINTEREST, INC. (PINS), CLICK HERE TO PARTICIPATE IN THE SECURITIE...

加州聖卡洛斯--(BUSINESS WIRE)--(美國商業資訊)-- BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235)是一家全球性腫瘤公司，今日公布HERIZON-GEA-01研究資料已刊登於The New England Journal of Medicine，並將於2026年6月1日於芝加哥舉行的美國臨床腫瘤學會(ASCO)年會上，以口頭報告（快速口頭報告：4010）形式發表。HERIZON-GEA-01臨床試驗評估ZIIHERA® (zanidatamab)聯合化療，並比較加入或不加入TEVIMBRA® (tislelizumab)的療效，對照組為trastuzumab聯合化療，用於一線治療晚期或轉移性HER2陽性胃食道腺癌。 韓國首爾延世大學醫學院延世癌症中心腫瘤內科教授，及該NEJM論文資深作者及ASCO摘要第一作者Sun Young Rha博士表示： 「HERIZON-GEA-01研究結果於The New England Journal of Medicine發表，並於ASCO口頭報告中公布，提供了關...

SAN CARLOS, California--(BUSINESS WIRE)--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), empresa global de oncología, anunció hoy que los datos del estudio HERIZON-GEA-01 fueron publicados en The New England Journal of Medicine y se presentarán en una exposición oral (Rapid Oral Abstract: 4010) durante la reunión anual de la American Society of Clinical Oncology (ASCO), que se celebrará el 1 de junio de 2026 en Chicago. El ensayo clínico HERIZON-GEA-01 evaluó ZIIHERA® (zanidatamab...

SAN CARLOS, Califórnia--(BUSINESS WIRE)--A BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), empresa global de oncologia, anunciou hoje que os dados do estudo HERIZON-GEA-01 foram publicados no The New England Journal of Medicine e serão apresentados em uma sessão oral (Resumo Oral Rápido: 4010) na Reunião Anual da Sociedade Americana de Oncologia Clínica (ASCO), que ocorrerá em 1º de junho de 2026, em Chicago. O ensaio clínico HERIZON-GEA-01 avaliou a associação de ZIIHERA® (zanida...